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There is a common consensus among practitioners that clinical practice guidelines (CPGs) 
improve care. [1] Moreover, CPGs empower patients to make informed healthcare choices, 
influence healthcare policies, promote distributive justice and advocate better delivery of 
services. However, it is currently unclear how key stakeholders (eg. patients, carers, 
charitable organisations, healthcare funders) can be active in the development and 
implementation of guidelines in a meaningful way alongside the traditional clinical and 
methodological membership. The hurdle of including key non-medical stakeholders is 
perceived as substantial despite patient-focused outcomes.  
 
CPGs could also work very effectively to promote user engagement in treatment choices and 
decision-making. Inclusion of patients and other key stakeholders could potentially facilitate 
direct discussions regarding the process of care, outcomes of importance, and patient 
preferences, while weighing experiential benefits and harms of different treatment regimens. 
[2] Ultimately, all parties would benefit from informed choice and improved treatment 
adherence. [3] Examples where patients are successfully engaged in specific circumstances 
include the James Lind Alliance methodology [4] and the COMET initiative for core outcome 
set development. [5] These coalitions represent excellent but isolated efforts which would 
ideally be “joined up” to a wider process subject to systematic evaluation.  
  
Here, we propose a model that addresses all different agents (patients, carers, charitable 
organisations, healthcare funders, in addition to specialists) involved in health-related 
decisions. Importantly, our proposed model incorporates key stakeholders as non-tokenistic 
panel members with clearly defined responsibilities (Box 1).  
 
The role of stakeholders in the development of CPGs should be shaped to minimize bias 
within this process. All panel members are expected to contribute appropriate comments to 
the discussion. [6] For patient-members, discussion needs to be framed in terms of the 
process of care, and how to prioritise clinical questions. [2] Importantly, the patient 
representative brings another perspective on the design and delivery of care to the discussion, 
rather than making decisions on which treatment is best. However, in helping to prioritise the 
outcomes of most importance in deciding whether one treatment is better than another, the 
patient voice is clearly important. 
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Three main models of how to elicit meaningful stakeholder participation in CPG development 
exist: (1) direct membership of the panel, (2) evaluation of evidence outside of panel 
meetings (e.g. through the formation of an expert patient guideline group, through a ‘one-off’ 
meeting or through a series of CPG workshops with stakeholders), or (3) having a “skilled 
member” to speak for the wider patient/stakeholder group (e.g. the director of a charity). [6] 
The “skilled member” model has been favored in practice, [2] but this raises the question of 
how this can then transcend individual bias, national boundaries, cultures, differences in the 
process of healthcare and how it is to be funded. Finally, there is a question of how the input 
of each panel member is assessed, in parallel with the evaluation of the guidelines 
themselves, and the costs/benefits of different stakeholder engagement. Measurable outcomes 
(e.g. adherence to CPGs, adherence to treatment, costs of care) will define CPG efficacy, 
together with qualitative outcomes such as patient-centred care, or shared-decision making.  
 
Proposed model: 
The core principles of CPG development are transparency, accountability, and the 
harmonisation of patient care based on the best available scientific evidence. We propose a 
feasible model, currently being operationalised by the European Association of Urology 
(EAU), for CPGs to serve key stakeholders, which will also benefit the implementation of 
guidelines (Figure 1).  
 
Firstly, an effective panel must be redefined. Historically, panels have grown organically 
from the network of the appointed chair/vice-chair. To professionalise this process, the skills 
and qualities/backgrounds desired for each seat should be defined a priori, and then 
appropriate members appointed in a transparent process, preferably balanced for area of 
expertise, gender, geography, experience and perspective. All members should be 
interviewed. Once appointed to a panel, members should go through methods training to 
serve a time-limited appointment.   
 
A guidelines panel should have at least one patient representative as a non-expert member, 
although preferably additional professionals allied to medicine could also be invited (nurse 
practitioners, social workers, healthcare economists, etc.). The selection procedure non-
medical members should be equally transparent. Ideally the patient advocate will be able to 
represent the broad interests of the target group and will have an education level appropriate 
to the tasks provided. Masterclasses like those provided by the European School of Oncology 
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aiming to train aspiring patient advocates to work with professionals to promote their interests 
should be considered as necessary investment. The non-medical panel members should be 
supported with appropriate-level material to enable participation in priority-setting, 
conveying patient-important outcomes, and CPG development.  
 
Importantly, we propose that the role of the patient advocate is to link the panel’s guidelines 
back to their national and international community to canvas opinion on priority setting and 
outcome measures (Figure 1). This feed-back/feed-forward loop will also contribute to the 
prioritisation of research. Current examples within Urology of the provision of evidence-
based care through a partnership between the clinical team, the patients and researchers 
include UCAN (Urological CANcer charity) and the IKCC (International Kidney Cancer 
Consortium), respectively. [12, 13-15, 16]. A key advantage of these linkages with large 
national and multinational stakeholder groups is that they are almost by definition trained at a 
professional level of communication with medical experts, pharmaceutical companies, and 
other patients alike.  
 
Conclusion: 
Patient advocates and other stakeholders can add substantial value to CPG development, 
dissemination and implementation. We propose modifying guidelines panel composition and 
using measurable outcomes to improve guidelines practice. Ineffective dissemination of 
recommendations risk variations in practice. Consequently, patients will not always receive 
the best possible care, with greater potential to experience harm. Furthermore, if all 
stakeholders, including patients, are meaningfully included in discussions about which 
research areas should be prioritised, what outcomes are of the highest importance, or which 
recommendations are made, then informed shared decision-making should result. In short, 
our model aspires to truly capture the voice of the local and national stakeholder communities 
and feed this forward to an international guideline panel to improve outcomes and adherence 
to CPGs. 
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Breakout	Box	1:				
	
Checklist	to	achieve	Multidisciplinary	Stakeholders	in	a	Clinical	Practice	Guideline	Panel:	
	
ü Define	the	remit	of	the	panel	and	the	roles	of	each	place	on	the	panel;	specify	rules	
for	the	process	
	
ü Identify	key	stakeholder	functions,	potential	members:		
Ø medical	specialists	
Ø junior	associates	able	to	generate	systemic	reviews	for	recommendations	
Ø non-medical	health	professionals	(nursing,	paramedical,	health	economist)	
Ø patient	representation	(determine	global/international/national)	
Ø healthcare	funders	
Ø charitable	organisations	
	
ü Interview	all	potential	members	for	skill-based	function	on	panel,	impartiality,	
transparency,	and	ability	to	commit	to	a	term	and	workload	
	
ü Assess	conflicts	of	interest	and	ensure	that	panel	members	do	not	vote	on	or	
influence	any	issues	where	they	are	conflicted	
	
ü Train	all	panel	members	in	evidence-based	medicine	methodologies	
	
ü Define	outreach	outcomes	per	member	(eg	for	the	patient	representative	feedback	
from	the	community,	priority	setting)	to	generate	feedback	cycle	
	
ü Evaluate	member	function	annually,	outcomes	delivered	
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